This recommendation applies to the routine Expanded Program of Immunisation, for travel, and reactive vaccination campaigns during epidemics and is supported by data on immunogenicity and safety of the yellow fever vaccine among HIV-infected people with CD4+ T-cell counts of at least 200 cells per mL.9 The gene discussed is CD4; the disease is viral infectious disease.